<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04199702</url>
  </required_header>
  <id_info>
    <org_study_id>2019P003413</org_study_id>
    <nct_id>NCT04199702</nct_id>
  </id_info>
  <brief_title>Feasibility and Safety of Same Day Discharge afTer Atrial Fibrillation Ablation</brief_title>
  <acronym>FAST-AF</acronym>
  <official_title>Feasibility and Safety of Same Day Discharge afTer Atrial Fibrillation Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Catheter ablation with pulmonary vein (PV) isolation is a commonly performed strategy&#xD;
      employed for the treatment of atrial fibrillation. The conventional approach for&#xD;
      post-procedure care has been for the patient to stay overnight and be discharged the next&#xD;
      day. However, the overall incidence of procedure related complications of catheter ablation&#xD;
      for atrial fibrillation in high volume centers is low. New technologies have been introduced&#xD;
      and improve the safety of the ablation procedure. Discharging patients the same day after&#xD;
      ablation is a practice that's currently followed by many centers in the United States and&#xD;
      abroad. The investigators' hypothesis is that the currently available advanced technologies&#xD;
      allow for the same-day safe discharge of patients after catheter ablation. The investigators&#xD;
      propose a prospective single-arm study to evaluate the feasibility and safety of the same-day&#xD;
      discharge after AF ablation at MGH. The protocol of same-day discharge will include the use&#xD;
      of a commercially available venous closure device, early ambulation, bed-side echocardiogram,&#xD;
      and follow-up phone calls at day 1 and 3 post-procedure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of successful same day discharge after AF ablation procedure</measure>
    <time_frame>Day of the AF ablation procedure</time_frame>
    <description>The rate of successful same day discharge after AF ablation procedure in more than 80% of cases that undergo the AF ablation procedure</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Same day discharge</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Same day discharge</intervention_name>
    <description>Patients will be discharged the same day they undergo catheter ablation of atrial fibrillation.</description>
    <arm_group_label>Same day discharge</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 - Age &lt; 75 yr&#xD;
&#xD;
          -  Documentation of atrial fibrillation (AF) or atypical atrial flutter&#xD;
&#xD;
          -  All patients must understand and adhere to the requirements of the study and be&#xD;
             willing to comply with the post study follow-up requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Heart failure with reduced ejection fraction less than 40%&#xD;
&#xD;
          -  Any reversible cause of AF (post-surgery, thyroid disorder, etc.)&#xD;
&#xD;
          -  INR &gt; 4.0 at the time of the procedure&#xD;
&#xD;
          -  Mental impairment precluding verbal consent or completing follow up&#xD;
&#xD;
          -  Patients with any other significant uncontrolled or unstable medical condition&#xD;
&#xD;
          -  Women who are known to be pregnant or have had a positive Î²-HCG test within 7 days&#xD;
             prior to procedure&#xD;
&#xD;
          -  Presence of left atrial thrombus&#xD;
&#xD;
          -  Patients with prior prostate hypertrophy or bladder surgery&#xD;
&#xD;
          -  BMI &gt; 40 or BMI &lt;20&#xD;
&#xD;
          -  Patients with h/o symptomatic heart failure&#xD;
&#xD;
          -  Patients with severe aortic stenosis (AS) or severe mitral regurgitation (MR)&#xD;
&#xD;
          -  Patients who require femoral arterial line for blood pressure monitoring&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Ha</last_name>
      <phone>617-643-1697</phone>
      <email>gha2@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>November 27, 2020</last_update_submitted>
  <last_update_submitted_qc>November 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Moussa C Mansour</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

